Tech Meridian ← ENTITY INDEX
PROMY MERIDIAN RU

COMPANY · ENTITY #6178

Novartis

Related event timeline, sources and context from the news index.

EVENT TIMELINE

2

STARTUPS · 2 SOURCES · TechCrunch AI · The Decoder

Isomorphic Labs raises $5B Series C to push AI-designed drug candidates toward clinical trials

Isomorphic Labs, the AI drug-discovery spinout from DeepMind, raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital with participation from Andreessen Horowitz and existing backers including GV, CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. The company says it will use the funding to further develop its AI drug-design engine — built on techniques from DeepMind’s AlphaFold work — and to advance AI-designed candidates that have shown reported positive preclinical results in oncology and immunology toward clinical trials; it has partnerships with Eli Lilly, Novartis and Johnson & Johnson and did not disclose a valuation (Bloomberg earlier reported it sought a $50 billion valuation).

8.0

COMPANIES · 1 SOURCE · The Decoder

Anthropic building San Francisco-area biology lab where Claude will guide robots

Anthropic is establishing a biology lab near San Francisco to run physical drug experiments with AI guidance; the company plans for Claude to direct robots through experiments using tools such as Claude Science and the Model Hardware Standard, with human oversight retained. The move follows Anthropic's acquisition of Coefficient Bio (about $400 million) and addition of Novartis CEO Vas Narasimhan to its board; Anthropic says it will not run clinical trials for now.

7.0